Methaneseleninic acid and γ-tocopherol combination inhibits prostate tumor growth in vivo in a xenograft mouse model

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3651-3661

  Singh, Chandra K ^a   Ndiaye, Mary A ^a   Siddiqui, Imtiaz A ^a   Nihal, Minakshi ^a,c   Havighurst, Thomas ^b   Kim, KyungMann ^b,c   Zhong, Weixiong ^b,c   Mukhtar, Hasan ^a,c   Ahmad, Nihal ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Chemoprevention; Prostate cancer; SELECT; Selenium; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; CHOLESTEROL; GAMMA TOCOPHEROL; KI 67 ANTIGEN; METHANESELENINIC ACID; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; SELENIUM; SELENOPROTEIN P; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; METHYLSELENIC ACID; ORGANOSELENIUM DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GLEASON SCORE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER CELL LINE; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; MALE; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GAMMA-TOCOPHEROL; HUMANS; MALE; MICE; MICE, NUDE; ORGANOSELENIUM COMPOUNDS; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903532811     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1979     Document Type: Article

References (40)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
2. Clark LC, Dalkin B, Krongrad A, Combs GF, Jr., Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S and Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol. 1998; 81(5):730-734.
3. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Eng J Med. 1994; 330(15):1029-1035.
4. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M and Edwards BK. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998; 90(6):440-446.
5. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009; 301(1):39-51.
6. Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011; 306(14):1549-1556.
7. Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology. 2002; 59(4 Suppl 1):9-19.
8. Ledesma MC, Jung-Hynes B, Schmit TL, Kumar R, Mukhtar H and Ahmad N. Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med. 2011; 17(1-2):134-143.
9. Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids. J Am Diet Assoc. 2000; 100(6):637-640.
10. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr., Park HK, Sanders BB, Jr., Smith CL and Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276(24):1957-1963.
11. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142(1):37-46.
12. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Jr., Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005; 97(2):94-102.
13. Yang CS, Suh N and Kong AN. Does vitamin E prevent or promote cancer? Cancer Prev Res (Phila). 2012; 5(5):701-705.
14. Ju J, Hao X, Lee MJ, Lambert JD, Lu G, Xiao H, Newmark HL and Yang CS. A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice. Cancer Prev Res (Phila). 2009; 2(2):143-152.
15. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato SY, Kuriyama H, Nakadate M, Abe K, Maeno Y, Nagao M and Shirai T. Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate. 2009; 69(6):644-651.
16. Lu G, Xiao H, Li GX, Picinich SC, Chen YK, Liu A, Lee MJ, Loy S and Yang CS. A gamma-tocopherol-rich mixture of tocopherols inhibits chemically induced lung tumorigenesis in A/J mice and xenograft tumor growth. Carcinogenesis. 2010; 31(4):687-694.
17. Barve A, Khor TO, Nair S, Reuhl K, Suh N, Reddy B, Newmark H and Kong AN. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer. 2009; 124(7):1693-1699.
18. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, Combs GF, Jr. and Lu J. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis. 2008; 29(5):1005-1012.
19. Zhang J, Wang L, Li G, Anderson LB, Xu Y, Witthuhn B and Lu J. Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr Cancer. 2011; 63(5):778-789.
20. Yan L and DeMars LC. Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice. Int J Cancer. 2012; 131(6):1260-1266.
21. Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D and Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999; 35(7):403-409.
22. Venanzoni MC, Giunta S, Muraro GB, Storari L, Crescini C, Mazzucchelli R, Montironi R and Seth A. Apolipoprotein E expression in localized prostate cancers. Int J Oncol. 2003; 22(4):779-786.
23. Mazur A, Nassir F, Gueux E, Moundras C, Bellanger J, Grolier P, Rock E and Rayssiguier Y. Diets deficient in selenium and vitamin E affect plasma lipoprotein and apolipoprotein concentrations in the rat. Br J Nutr. 1996; 76(6):899-907.
24. Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, Campion J, Endermann T, Takahashi K, Saito Y, Catena R, Schomburg L and Calvo A. Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. Prostate. 2011;71(8):824-834.
25. Huang Y, Khor TO, Shu L, Saw CL, Wu TY, Suh N, Yang CS and Kong AN. A gamma-tocopherol-rich mixture of tocopherols maintains Nrf2 expression in prostate tumors of TRAMP mice via epigenetic inhibition of CpG methylation. J Nutr. 2012; 142(5):818-823.
26. Klein EA and Thompson IM. Chemoprevention of prostate cancer: an updated view. World J Urol. 2012; 30(2):189-194.
27. Reagan-Shaw S, Nihal M and Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008; 22(3):659-661.
28. Munoz E, Gomez F, Paz JI, Casado I, Silva JM, Corcuera MT and Alonso MJ. Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation. Eur J Histochem. 2003; 47(2):123-128.
29. McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA and Steele VE. Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila). 2010; 3(3):381-392.
30. Reagan-Shaw S, Nihal M, Ahsan H, Mukhtar H and Ahmad N. Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate. 2008; 68(15):1624-1634.
31. TzifiF, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S and Scorilas A. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Adv Hematol. 2012; 2012:524308.
32. Karnak D and Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets. 2010; 11(6):699-707.
33. Iannolo G, Conticello C, Memeo L and De Maria R. Apoptosis in normal and cancer stem cells. Crit Rev Oncol Hematol. 2008; 66(1):42-51.
34. Gupta-Elera G, Garrett AR, Robison RA and O'Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev. 2012; 21(2):155-162.
35. Sikka SC. Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention-a mechanistic approach. Curr Med Chem. 2003; 10(24):2679-2692.
36. Acharya A, Das I, Chandhok D and Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev. 2010; 3(1):23-34.
37. Terazawa R, Garud DR, Hamada N, Fujita Y, Itoh T, Nozawa Y, Nakane K, Deguchi T, Koketsu M and Ito M. Identification of organoselenium compounds that possess chemopreventive properties in human prostate cancer LNCaP cells. Bioorg Med Chem. 2010; 18(19):7001-7008.
38. Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Simoes BP, de Souza AM and Castro FA. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis. J Hematol Oncol. 2012; 5:2.
39. Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H and Yasui W. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 2004; 64(7):2397-2405.
40. Albrecht AL, Somji S, Sens MA, Sens DA and Garrett SH. Zinc transporter mRNA expression in the RWPE-1 human prostate epithelial cell line. Biometals. 2008; 21(4):405-416.